You are here:
Home / Archives for Keryx Biopharmaceuticals
We, at biotuesdays.com, attended Dundee Capital Markets’ second emerging growth conference last week, where over 20 technology, life sciences and industrial growth companies presented. Dundee specializes in early-stage growth, and to say that the one-day showcase was jammed full of investment ideas is a bit of understatement. Here’s a sampling of what we took away [...]
Filed under Tuesday Features · Tagged with Aeterna Zentaris, AEZS-108 compound, Alnylam Pharmaceuticals, Bioniche Life Science, blood-based diagnostic tests, ColonSentry, David Martin, Dennis Turpin, DepoVax platform, DPX-0907, Dr. Fahar Merchant, Dr. Mark Murray, Dr. Randal Chase, Dundee Capital Markets, EMD 640744, endo pharmaceuticals, Enzo Clinical Labs, fluorescence imaging technologies, Gailina Liew, GeneNews, Handok Pharmaceuticals, Immunovaccine, infectious disease and therapeutic cancer vaccines, INxin, Keryx Biopharmaceuticals, LifeCell, Medicago Inc., multiple myeloma and colorectal cancer, NASDAQ:ENDP, Novadaq Technologies, perifosine, Pfizer Animal Health, Pierre Labbé, PORxin, Proficia, Protox Therapeutics, PRX302, PRX321, RNA-interference delivery, Sentinel Principle, SPY imaging system, Tekmira Pharmaceuticals, Transformational Medical Technologies, Urocidin, Virus-Like Particles
Listen to BioTuesdays 
